Literature DB >> 10579796

Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer.

D Strohmeyer1, C Rössing, F Strauss, A Bauerfeind, O Kaufmann, S Loening.   

Abstract

BACKGROUND: The clinical relevance of tumor angiogenesis has been investigated in several human tumor types. Angiogenesis (measured as microvessel density; MVD) was recently correlated with tumor stage, grade, and clinical course in prostate cancer (PC). However, considerable controversy remains concerning the prognostic value of angiogenesis in PC.
METHODS: We examined MVD in primary PCs to further establish the prognostic relevance of angiogenesis in this tumor entity. In 98 paraffin-embedded PCs of various stages, 5 prostate adenomas, and 20 normal prostate tissues, MVD was determined immunohistochemically using a polyclonal antibody against factor VIII. The findings were correlated with the clinical data of the patients.
RESULTS: Normal prostate tissue and prostate adenomas had a low MVD. In PC, MVD increased significantly with tumor stage and grade (P < 0.001). The Wilcoxon rank statistics showed significant differences for MVD (P < 0.0001), tumor stage (P < 0. 0027), and grade (P < 0.0001), but not for preoperative prostate-specific antigen values in PC patients with and without tumor progression subsequent to treatment, respectively. Importantly, multivariate survival analysis revealed that MVD and tumor grade were the only independent markers for progression in prostate carcinoma.
CONCLUSIONS: In this study, tumor angiogenesis measured by MVD was associated with a dismal pathologic appearance and a negative clinical prognosis in PC after radical prostatectomy. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2000        PMID: 10579796     DOI: 10.1002/(sici)1097-0045(20000101)42:1<26::aid-pros4>3.0.co;2-6

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  29 in total

1.  Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer.

Authors:  Danni Li; Hanching Chiu; Vinita Gupta; Daniel W Chan
Journal:  Clin Chim Acta       Date:  2012-06-18       Impact factor: 3.786

Review 2.  A comparison of the diagnostic performance of systematic versus ultrasound-guided biopsies of prostate cancer.

Authors:  Stijn W T P J Heijmink; Hilco van Moerkerk; Lambertus A L M Kiemeney; J Alfred Witjes; Ferdinand Frauscher; Jelle O Barentsz
Journal:  Eur Radiol       Date:  2006-01-04       Impact factor: 5.315

Review 3.  Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant.

Authors:  Amelia Altavilla; Roberto Iacovelli; Giuseppe Procopio; Daniele Alesini; Emanuela Risi; Giuseppe Maria Campennì; Antonella Palazzo; Enrico Cortesi
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

Review 4.  Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate.

Authors:  Alejandro S Godoy; Ivy Chung; Viviana P Montecinos; Ralph Buttyan; Candace S Johnson; Gary J Smith
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-04-02       Impact factor: 4.310

5.  The role of magnetic resonance imaging (MRI) in prostate cancer imaging and staging at 1.5 and 3 Tesla: the Beth Israel Deaconess Medical Center (BIDMC) approach.

Authors:  B Nicolas Bloch; Robert E Lenkinski; Neil M Rofsky
Journal:  Cancer Biomark       Date:  2008       Impact factor: 4.388

6.  ADAMTS1 alters blood vessel morphology and TSP1 levels in LNCaP and LNCaP-19 prostate tumors.

Authors:  Heléne Gustavsson; Tajana Tesan; Karin Jennbacken; Kouji Kuno; Jan-Erik Damber; Karin Welén
Journal:  BMC Cancer       Date:  2010-06-14       Impact factor: 4.430

7.  Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer.

Authors:  N M Corcoran; C M Hovens; M Michael; M A Rosenthal; A J Costello
Journal:  Br J Cancer       Date:  2010-07-20       Impact factor: 7.640

8.  Prognostic value of microvessel density in prostate cancer: a tissue microarray study.

Authors:  Andreas Erbersdobler; Hendrik Isbarn; Kira Dix; Isabel Steiner; Thorsten Schlomm; Martina Mirlacher; Guido Sauter; Alexander Haese
Journal:  World J Urol       Date:  2009-08-28       Impact factor: 4.226

Review 9.  VEGF inhibitors and prostate cancer therapy.

Authors:  Jeanny B Aragon-Ching; William L Dahut
Journal:  Curr Mol Pharmacol       Date:  2009-06       Impact factor: 3.339

Review 10.  Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer.

Authors:  William D Figg; Erwin A Kruger; Douglas K Price; Sonia Kim; William D Dahut
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.